The transplantation of mobilised peripheral blood stem cells is associated with more rapid engraftment than marrow transplantation. We have previously reported that G-IVE (G-CSF, ifosphamide, VP-16, epirubicin) improves the yield of CD34
The use of high-dose chemo-radiotherapy and autologous stem cell support is established therapy in the management of patients with relapsed Hodgkin's disease and high-grade non-Hodgkin lymphoma (NHL) [1] [2] [3] and is increasingly being used in patients with low-grade NHL. [4] [5] [6] [7] [8] [9] PBSC are now preferred over autologous bone marrow (BM) to support these therapies 10 as their use is associated with more rapid engraftment of both neutrophils and platelets, reduced blood product and antibiotic requirements and reduced inpatient stay. [11] [12] [13] [14] A number of studies have shown that the speed of engraftment post transplant is correlated with the number of CD34 ϩ cells transplanted. [15] [16] [17] [18] Early studies suggested that transplantation of a CD34 ϩ cell dose of Ͼ2-5 ϫ 10 6 /kg is associated with optimal haemopoietic recovery following high-dose therapy although more recent studies suggest that engraftment may be further accelerated by the transplantation of larger numbers of CD34 ϩ cells. 19, 20 It is clear that previous chemotherapy and radiotherapy can impair the mobilisation of sufficient CD34 ϩ to proceed with transplantation. Furthermore, it has also been reported that in patients with previously treated low-grade lymphoma stem cell mobilisation often results in poor progenitor cell yields, 21, 22 which may be a consequence of previous exposure to alkylating agents such as chlorambucil and purine analogues which are commonly used as initial treatment in these disorders.
We have previously reported the use of G-IVE as a combined salvage and mobilisation schedule in a small series of patients with lymphoma considered for high-dose therapy. 23 We showed that patients treated with G-IVE mobilised significantly more CD34 ϩ cells than those treated with cyclophosphamide and G-CSF (G/CYCLO) and that G-IVE was successful in mobilising CD34 ϩ cells in patients who had failed mobilisation with G/CYCLO. In the present study we have extended our experience with G-IVE as a mobilisation schedule in a larger series of lymphoma patients which demonstrates the efficacy of this regimen for PBSC mobilisation and furthermore is clearly superior to cyclophosphamide and G-CSF in all subtypes of lymphoma.
Patients and methods

Mobilisation
Ninety-seven consecutive patients with lymphoma undergoing initial PBSC mobilisation with G/CYCLO and G-IVE in Nottingham between June 1992 and July 1998 were considered in the analysis. Fifty-five patients were mobilised with G/CYCLO from June 1992 until July 1995 when a policy decision led to the introduction of G-IVE for combined salvage therapy and mobilisation which has become our standard approach. Overall, 32 patients had high-grade NHL, 37 had low-grade NHL and 28 patients had Hodgkin's disease. Patient details are given in Table  1 . There were no statistically significant differences in patient age, diagnosis or previous chemotherapy or radiotherapy between the two groups although 29% of the patients mobilised with G/CYCLO had received three or more courses of previous chemotherapy compared with 21% of G-IVE patients. Patients who failed mobilisation and were then re-mobilised with one of the above regimens were excluded from the analysis.
Previous therapies
Low-grade non-Hodgkin's lymphoma: Patients were initially treated with oral chemotherapy with chlorambucil ± prednisilone. Local radiotherapy was given as necessary. Only three patients had received previous fludarabine ther- Table 1 Characteristics of patients receiving C/G-CSF and G-IVE as initial mobilisation 24 Salvage therapy was dependent on initial therapy. Radiotherapy was used for early stage disease and at sites of bulk and/or residual disease.
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Mobilisation regimens
Cyclophosphamide 3 g/m 2 (n = 47) or 4 g/m 2 (n = 8), was used for 55 mobilisation procedures (G/CYCLO). G-CSF 300 g s.c. was started at day ϩ5 and leucapheresis performed using a Fenwall CS3000ϩ (Baxter, Deerfield, IL, USA) and initiated as the total white cell count rose through 4 ϫ 10 9 /l as previously reported. 18 Leucaphereses (2.5 times blood volume) were performed daily with the aim of collecting Ͼ2.5 ϫ 10 6 /kg CD34 ϩ cells. The PBSC harvests were cryopreserved in 10% DMSO and stored in the vapour phase of liquid nitrogen.
Forty-two patients received G-IVE for mobilisation consisting of ifosphamide 3 g/m 2 daily for 3 days, etoposide 200 mg/m 2 daily for 3 days and epirubicin 50 mg/m 2 on day 1. As with cyclophosphamide, G-CSF (300 g s.c.) administration was delayed until day ϩ5 (G-IVE). The dose of G-CSF in these studies was constant and not altered according to the patients' weight. Details of leucapheresis were identical to those described for C/G-CSF and the same target dose of CD34 ϩ cells was used.
Flow cytometric analysis
As previously described, harvest quality was assessed using FACScan (Becton Dickinson, San José, CA, USA) analysis of the CD34 ϩ population. 23, 25 Briefly 100 l cells were incubated separately with 5 l phycoerythrin and FITC conjugated anti-HPCA-2 (Becton Dickinson) in 895 l 1% PBS albumin for 10 min at room temperature. Cells were washed twice in 0.01% PBS azide, fixed in 1% paraformaldehyde and red cells lysed with FACSlyse solution (Becton Dickinson). CD34
ϩ cell analysis was performed on SSC vs fluorescence plots after gating on the CD45 ϩ population (50 000 events). 15 
Haemopoietic culture assays
Clonogenic assays for haemopoietic progenitors were performed in 1.3% methylcellulose (Sigma, Poole, UK) with 20% foetal calf serum (Advanced Protein Products, Brierly Hill, UK). Cultures were stimulated with 10 5 /ml IL-3 (Behring, Marburg, Germany) and 10 5 /ml GM-CSF (Glaxo, Geneva, Switzerland). Cells (1 ϫ 10 5 /ml) were plated in triplicate in 35-mm Petri dishes and incubated at 37°C in humidified 5% CO 2 . Colonies (Ͼ50 cells) were scored after 14 days with an inverted microscope.
Engraftment
An analysis of engraftment and its relationship to the number of CD34 ϩ cells transplanted was assessed in 104 patients receiving unmanipulated PBSC transplants. This included 67 of the 97 patients in the mobilisation analysis and in addition 37 patients with myeloma, all mobilised with G/CYCLO. Thirty patients with lymphoma were excluded from the engraftment analysis as they either underwent CD34
ϩ cell selection prior to transplant or did not proceed to high-dose therapy at all. Patients undergoing CD34 selection were excluded on the grounds that the selection procedure itself might adversely affect engraftment characteristics of the infused CD34 ϩ cells. The lymphoma patients received high-dose chemotherapy with BEAM (n = 61), or melphalan and etoposide (n = 4) or cyclophosphamide 120 mg/kg and TBI (12 Gy ) from day ϩ1 post-transplant. This was introduced in January 1996 and followed a previous report from our group which demonstrated a beneficial effect on engraftment. 26 
Statistical analysis
All analyses were performed using SPSS 7.0 for Windows (SPSS Inc, Chicago, IL, USA). Median values for the parameters analysed were compared using the Mann-Whitney U test. The chi-squared test was used for nominal data. Engraftment data were compared using the log-rank test. A P value Ͻ0.05 was considered significant.
Results
PBSC mobilisation in all lymphoma patients
In this analysis, 42 patients underwent mobilisation with G-IVE. Their clinical details are given in Table 1 along with those of the 55 patients receiving G/CYCLO. There were no significant differences between the two groups in relation to the amount of previous chemotherapy or radiotherapy. Overall, patients receiving G-IVE mobilised significantly more CD34 ϩ cells per leucapheresis, a median of 5.82 ϫ 10 6 /kg compared with 1.2 ϫ 10 6 /kg for patients receiving G/CYCLO, P Ͻ 0.001 (Table 2 ). This resulted in collection of significantly more CD34 ϩ cells in those patients receiving G-IVE: a median of 6.78 ϫ 10 6 /kg compared with 3.59 ϫ 10 6 /kg for those receiving G/CYCLO, P = 0.001. This also resulted in a significant reduction in the number of leucaphereses required to collect sufficient CD34 ϩ cells to proceed with transplantation, a median of one leucapheresis (1-6) compared with two (1-5) for patients receiving G/CYCLO, P Ͻ 0.001. 6 /kg and 3.91 (0.10-36) ϫ 10 6 /kg total CD34 ϩ cells (P = 0.02 and P = 0.03, respectively). There were no significant differences in the total number of CD34 ϩ cells per leucapheresis and total harvested number of CD34 ϩ cells in patients with LGNHL or HD (P = 0.58 and 0.64, respectively). A comparison of G-IVE mobilisation with G/CYCLO mobilisation was performed in the three disease subtypes. These data are presented in Table 2 . In all three groups, G-IVE mobilised significantly more CD34 
PBSC mobilisation dependent on lymphoma subtype
The effect of CD34
ϩ cell number infused on engraftment
The effect of CD34 ϩ cell dose infused on engraftment was analysed in 106 patients with lymphoma and myeloma ( Table 3 ). All these patients received an unmanipulated graft and 59 patients received low-dose G-CSF (50 g/m 2 ) from day ϩ1 post transplantation. Patients were grouped depending on the number of CD34 ϩ cells transplanted: group 1 received Ͻ2. /l a median of 27 (15-Ͼ300) days post transplant, those in group 2 took 13 (9-28) and 18 (11-55) days, respectively, group 3 patients 11.5 (8-20) and 16 (10-38) days, respectively, and group 4 patients (receiving Ͼ10 ϫ 10 6 /kg CD34 ϩ cells), 10 (7-20) and 13 (9-22) days, respectively (Figure 1a and b) . Using the log rank test to compare consecutive groups, each increment of CD34 ϩ cells transplanted was associated with a significant improvement in platelet engraftment, (group 1 vs group 2, /kg compared with 62% of patients mobilised with G/CYCLO, P = 0.004. Also for the higher CD34 ϩ cell dose 67% compared with 33%, respectively, achieved a total collection of Ͼ5 ϫ 10 6 /kg (P = 0.001), and 31% compared with 15%, respectively, collected Ͼ10 ϫ 10 6 /kg CD34 ϩ cells (P = 0.05).
Mobilisation targets
Discussion
We have previously reported that combined mobilisation and salvage with G-IVE was more effective than G/CYCLO. 23 Now in a larger series of 42 patients receiving G-IVE as mobilisation therapy we have confirmed those initial observations and have extended these observations to show that these benefits are seen in all subtypes of lymphoma patients. Significantly more CD34 ϩ cells per leucapheresis were mobilised in patients receiving G-IVE compared with those receiving G/CYCLO and this resulted in significantly more total CD34 ϩ cells being mobilised and consequently, fewer leucaphereses were required to collect sufficient CD34 ϩ cells to proceed with transplantation. The G/CYCLO group contained proportionately more patients with Hodgkin's disease and low-grade NHL as well as patients receiving slightly more chemotherapy and radiotherapy. However, although patients with high-grade NHL mobilised significantly better than those with LGNHL or Hodgkin's disease, in all lymphoma sub-groups mobilisation with G-IVE was associated with mobilisation of significantly more CD34 ϩ cells than G/CYCLO. Therefore in this larger study, we have been able to demonstrate that the improvement in CD34 ϩ cell yields achieved using G-IVE is attainable not just in patients who may be regarded as good mobilisers (ie high-grade NHL) but also in those patients with Hodgkin's disease and low-grade lymphoma who have previously been reported to be difficult to mobilise successfully. 17, 21, 22 In particular, Perry et al 21 have We have previously analysed and published our own mobilisation and engraftment data for patients with lymphoproliferative disorders undergoing mobilisation with G/CYCLO and have shown that transplantation of Ͼ2.5 ϫ 10 6 /kg CD34 ϩ cells was associated with rapid engraftment in most cases. 18 Using this threshold as a target for CD34 ϩ cell collection the use of G-IVE was again associated with an overall significantly lower failure rate compared with G/CYCLO: 12% compared with 38%. However, others have suggested that higher numbers of CD34 ϩ cells of Ͼ5.0 ϫ 10 6 /kg may further shorten engraftment times, particularly platelet recovery. 20 Also, Ketterer et al have reported that in patients with lymphoproliferative diseases, those transplanted with Ͼ15 ϫ 10 6 /kg CD34 ϩ cells had significantly more rapid platelet engraftment and a shorter duration of hospitalisation compared with patients transplanted with fewer cells. A re-analysis of engraftment in our series of 101 patients undergoing unmanipulated PBSC transplantation for lymphoma or myeloma has confirmed this finding. We found that the transplantation of increasing numbers of CD34 ϩ cells resulted in a significantly more rapid platelet engraftment with each incremental level of CD34 ϩ cells with the most rapid engraftment seen in those patients transplanted with Ͼ10 ϫ 10 6 /kg CD34 ϩ cells. Although only 16 patients in this study achieved that threshold, this underestimates the number of patients who could reach this threshold with G-IVE mobilisation, as our policy was to terminate the stem cell collection once Ͼ2.5 ϫ 10 6 /kg CD34 ϩ cells had been collected. As the median CD34 ϩ cell yield per leucapheresis was 5.82 ϫ 10 6 /kg for patients receiving G-IVE, it should be possible to obtain Ͼ10 ϫ 10 6 /kg CD34 ϩ cells in the majority of lymphoma patients with just two leucaphereses.
It is likely that the beneficial effect of a large CD34 ϩ cell dose has not been detected in previous studies because of the relatively few patients included who have mobilised 721  Table 4 Total number of patients achieving target numbers of mobilised CD34
+ cells /kg) of CD34 ϩ cells. [16] [17] [18] Although there did appear to be an improvement in neutrophil engraftment with transplantation of increasing numbers of CD34 ϩ cells this effect was not as pronounced as the improved platelet engraftment. This is most likely due to the fact that many (59/104) patients analysed in this study received post-transplant G-CSF to hasten neutrophil recovery. However it is clear from this study and others 19, 20 that transplantation of increasing numbers of CD34 ϩ cells results in prompter engraftment and therefore regimens which are effective in mobilising large numbers of CD34 ϩ cells are of value.
G-IVE is one of a number of second generation mobilising regimens which have been used as combined salvage and mobilisation therapy in patients with lymphoma. Aurlien et al 27 have reported the use of MIME chemotherapy (mitoguazon, ifosphamide, methotrexate and epirubicin) in 50 patients with previously treated lymphoma. Ninety-four per cent of patients achieved a CD34 ϩ cell target dose of Ͼ2.0 ϫ 10 6 /kg and they found this regimen to be a more effective and less toxic combination for mobilisation than Dexa-BEAM which has also been used for combined salvage and mobilisation. Martinez et al 28 have used IAPVP (ifosphamide, etoposide, Ara-C and methyl prednisolone) combined with G-CSF and achieved their CD34 ϩ cell target of 3.5 ϫ 10 6 /kg in 15 out of 15 patients. Other reported salvage and mobilisation regimens in patients with lymphoma include VAPEC-B and ESHAP. 29, 30 Although no randomised comparisons between mobilisation regimens have been reported these regimens would appear to mobilise better yields of CD34 ϩ cells than cyclophosphamide and G-CSF with the added advantages that they have specific anti-lymphoma activity and obviate the need for a specific mobilisation step. Further studies are required to determine if any one of these protocols has any specific advantages over the others.
In conclusion therefore, in patients with lymphoma G-IVE appears a superior regimen for CD34 ϩ cell mobilisation than G/CYCLO. Its use is associated with improved stem cell mobilisation in patients with low-grade lymphoma and Hodgkin's disease in whom mobilisation of adequate stem cells for transplantation has proved difficult in previous studies. This regimen has the advantage that more patients will mobilise sufficient CD34 ϩ cells to proceed to high-dose therapy and more patients may mobilise higher numbers of CD34 ϩ cells resulting in more rapid engraftment post transplant. Furthermore G-IVE is well tolerated and has proven activity in patients with all types of relapsed lymphoma with overall response rates of 60-90%. 31, 32 Randomised studies will be required to determine if any of the other combination regimens in current clinical use have any advantages over G-IVE.
